Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI117125

A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan).

R M Silver, A Ludwicka, M Hampton, T Ohba, S A Bingel, T Smith, R A Harley, J Maize, and M P Heyes

Department of Medicine, Medical University of South Carolina, Charleston 29425.

Find articles by Silver, R. in: PubMed | Google Scholar

Department of Medicine, Medical University of South Carolina, Charleston 29425.

Find articles by Ludwicka, A. in: PubMed | Google Scholar

Department of Medicine, Medical University of South Carolina, Charleston 29425.

Find articles by Hampton, M. in: PubMed | Google Scholar

Department of Medicine, Medical University of South Carolina, Charleston 29425.

Find articles by Ohba, T. in: PubMed | Google Scholar

Department of Medicine, Medical University of South Carolina, Charleston 29425.

Find articles by Bingel, S. in: PubMed | Google Scholar

Department of Medicine, Medical University of South Carolina, Charleston 29425.

Find articles by Smith, T. in: PubMed | Google Scholar

Department of Medicine, Medical University of South Carolina, Charleston 29425.

Find articles by Harley, R. in: PubMed | Google Scholar

Department of Medicine, Medical University of South Carolina, Charleston 29425.

Find articles by Maize, J. in: PubMed | Google Scholar

Department of Medicine, Medical University of South Carolina, Charleston 29425.

Find articles by Heyes, M. in: PubMed | Google Scholar

Published April 1, 1994 - More info

Published in Volume 93, Issue 4 on April 1, 1994
J Clin Invest. 1994;93(4):1473–1480. https://doi.org/10.1172/JCI117125.
© 1994 The American Society for Clinical Investigation
Published April 1, 1994 - Version history
View PDF
Abstract

The eosinophilia-myalgia syndrome (EMS) is a recently described disease that has been associated with the ingestion of L-tryptophan containing trace amounts of several impurities. The first such contaminant to be identified and linked epidemiologically to the EMS epidemic was 1,1'-ethylidenebis(L-tryptophan) (EBT), but its role in the etiology and pathogenesis of the syndrome has been controversial. We report the development of inflammation and fibrosis affecting the dermis and subcutis, including the fascia and perimyseal tissues, after the daily intraperitoneal administration of EBT to female C57BL/6 mice. Such changes are accompanied by increased numbers of mast cells, many of which appear to be degranulating. Plasma levels of quinolinic acid, a metabolic product of L-tryptophan via the kynurenine pathway, are reduced initially, and then become elevated when inflammation and fibrosis are more pronounced. The nature and location of the inflammatory cell infiltrate and fibrosis, as well as the presence of mast cells and alterations of L-tryptophan metabolism, are consistent with findings reported in patients with EMS. This murine model suggests that EBT may have been one of the mediators of EMS and should facilitate studies of the pathogenesis of EMS.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1473
page 1473
icon of scanned page 1474
page 1474
icon of scanned page 1475
page 1475
icon of scanned page 1476
page 1476
icon of scanned page 1477
page 1477
icon of scanned page 1478
page 1478
icon of scanned page 1479
page 1479
icon of scanned page 1480
page 1480
Version history
  • Version 1 (April 1, 1994): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts